Pre-approval and post-approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: a comparison with standard approved cancer drugs.

Lourens T BloemRosalinde E BotAukje K Mantel-TeeuwisseMenno E van der ElstGabe S SonkeOlaf H KlungelHubert G M LeufkensJarno Hoekman

Published in: British journal of clinical pharmacology (2021)

While CMA cancer indications are initially associated with less comprehensive evidence than SMA indications, levels of evidence and clinical benefit are similar after conversion from CMA to SMA.

Keyphrases

papillary thyroid
squamous cell
drug administration
lymph node metastasis